Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test
Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test
Contenu indisponible. Consultez la source originale.
Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test